The Watts Law Firm in San Antonio has filed a Motion before the Judicial Panel on Multidistrict Litigation to create an MDL for all federal personal injury and wrongful death cases related to the drug Pradaxa. The Motion was filed May 30, 2012, requesting that the pending cases throughout the country be consolidated in the U.S. District Court for the Southern District of Illinois.
Yesterday I posted that Pradaxa is a direct thrombin inhibitor prescribed to reduce the risk of stroke and embolism in people with nonvalvular atrial fibrillation. It is reported that several people taking the drug have experienced uncontrolled and excessive bleeding for which there is no reversing agent available at this time.
The Motion states:
“In their direct to consumer advertisements, Defendants overstated the efficacy of Pradaxa with respect to preventing stroke and systemic embolism and failed to adequately disclose to patients that there is no reversal agent or adequate means by which to reverse the anticoagulation effects of Pradaxa, and that such irreversibility could have permanently disabling, life-threatening and fatal consequences.”
If you are wondering how many people are effected by this drug, approximately 275,000 prescriptions were written for Pradaxa during the time period between approval by the FDA and March 2011. Reports of 932 serious adverse events including 120 deaths and 500 reports of severe, life threatening bleeding are stated in the Motion.
Drive Safe – XTHATXT
Say No to Distracted Driving